IL2 and type 1 diabetes mellitus: Other reports on low dose IL-2 treatment following polyclonal Treg therapy in cGvHD did not show clear additional effects (53), whereas a phase I study combining autologous ex vivo expanded polyclonal Tregs and low-dose IL-2 in patients with recent-onset T1D has been reported to enhance Treg survival and expansion.